newsfilter
← Latest News
Business Wire·

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Announced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE); data highlighted rapid and sustained